Navigation Links
Neuropathy in Medical Technology

Arcion Therapeutics' Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy

... significantly reduced pain caused by diabetic neuropathy in a double-blind, placebo-controlled trial. The ... of ARC-4558 for the treatment of painful diabetic neuropathy (PDN). According to the abstract, patients ... the study. About Painful Diabetic neuropathy (PDN) ...

Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma

... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ... diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral ...

Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients

... diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy and peripheral neuropathy aggravated) (39%), thrombocytopenia and appetite ...

Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients

... diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy and peripheral neuropathy aggravated) (39%), thrombocytopenia and appetite ...

Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives

... trials ongoing for the treatment of diabetic neuropathy (DN) and one to evaluate its use in the treatment ... of SB-509 in subjects with diabetic neuropathy (DN) demonstrating that the drug is ... and clinical effect in patients with diabetic neuropathy and ALS. Other therapeutic development programs ...

Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)

... additional Phase 2 clinical trials for diabetic neuropathy and stem cell mobilization. VEGF-A has been shown ... Phase 1 clinical studies of SB-509 in diabetic neuropathy have shown that the drug is well tolerated. Data ... and clinical effect in patients with diabetic neuropathy and ALS. Other therapeutic development programs ...

New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients

... (49% vs 46%), nausea (48% vs 28%), peripheral neuropathy (47% vs 5%), diarrhea (46% vs 17%), anemia (43% ... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell ...

Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting

... in subjects with mild to moderate diabetic neuropathy over the six month trial period after a single ... with mild to moderate diabetic peripheral neuropathy enrolled in Sangamo's Phase 1b study of SB-509 ... scoring systems. These include the Total neuropathy Score (TNS) and the narrower ...

Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma

... and neutropenia. No grade 4 peripheral neuropathy was observed. About Multiple Myeloma Multiple ... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ...

VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma

... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ... diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy and ...

New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma

... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ... diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy and ...

BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)

... reporting either severe sporadic or cumulative neuropathy was approximately 50% lower in the Tavocept arm ... discontinuance of chemotherapy treatment due to neuropathy in the Tavocept arm of the study, compared to the ... measured neuropathy only in terms of cumulative neuropathy and they were inconclusive. BioNumerik and ASKA ...

Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma

... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ... diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy and ...

Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results

... clinical development program in diabetic neuropathy and pre-IND programs to develop ZFP Therapeutics ... 1b study of SB-509 in subjects with diabetic neuropathy (DN). Data from the Phase 1b clinical trial ... in subjects with mild to moderate diabetic neuropathy over a six month period after a single ...

Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer

... with picoplatin exhibited a Grade 3 or higher neuropathy and only 9 of 45 patients (20 percent) experienced mild neuropathy. No neuropathy of Grade 2 or greater was observed in the 26 ... further evaluate efficacy and safety, including neuropathy of picoplatin in combination with 5-FU and LV ...

Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting

... mucositis/stomatitis (20% vs 5%), peripheral neuropathy (42% vs 45%), neuralgia (17% vs 20%), and rash ... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ...

Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy

... and a trend towards improvement in Total neuropathy Score (TNS), suggesting an alteration of disease ... to moderate diabetic peripheral sensory motor neuropathy in the legs. A total of 102 subjects have been ... and feet. The symptoms of diabetic peripheral neuropathy and any changes that occur during the trial will ...

New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma

... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ... diarrhea (52%), constipation (41%), peripheral neuropathy (39%), thrombocytopenia (36%), appetite decrease, ...

Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints

... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ... diarrhea (52%), constipation (41%), peripheral neuropathy (39%), thrombocytopenia (36%), appetite decrease, ...

Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma

... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ... diarrhea (52%), constipation (41%), peripheral neuropathy (39%), thrombocytopenia (36%), appetite decrease, ...

Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharma's Product Class

... activities. In this recently published study, a model of a human neuropathy was created in the fruit fly (Drosophila) by introducing mutations in the ... do not cause a loss in the protein synthesis activity, indicating that the neuropathy arises from distinct activities of this tRNA synthetase. This work ...

Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer

... of care for metastatic colorectal cancer, but is associated with severe neuropathy at increasing cumulative doses approaching 800 mg/meter squared. This ... showed evidence of severe neurotoxicity. Three different measurements of neuropathy were statistically significant for FOLPI as a potential neuropathy-sparing ...

Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology

... hematologic (p <0.001) and gastrointestinal (p = 0.004) adverse events. neuropathy occurred more frequently in the OPAXIO arm compared with the control arm (30 percent versus 5 percent, (p <0.001)), and grade 3 neuropathy occurred in 4 percent of the OPAXIO patients, with no occurrences of grade ...

Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs

... in subjects with moderate to severe diabetic peripheral sensory motor neuropathy (DN). The study is designed to evaluate the clinical safety and clinical ... of diabetic neuropathy. About Diabetic Neuropathy Diabetic peripheral neuropathy is one of the most frequent complications of diabetes. Symptoms include ...

Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients

... and reversible. Neutropenia was the dose-limiting toxicity (DLT). Mild neuropathy (grade 1) was observed in 3 of 33 patients (9 percent) and was unrelated to cumulative picoplatin dose. Neuropathy was infrequent, and no neuropathy of grade 2 or greater was observed. PSA response rate was 65 percent (20 ...

Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency

... is prescribed in combination with other anti-myeloma therapies. Peripheral neuropathy is a potentially severe, adverse effect of treatment with Thalidomide that ... not be used in patients with clinical signs or symptoms of peripheral neuropathy unless the clinical benefits outweigh the risks. Symptoms may occur some ...

Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology

... 1.0 to 1.3 mg/mm2. No dose- limiting toxicity and no grade 3 peripheral neuropathy were reported. Toxicities were generally well managed and ... perifosine regimen. Toxicity was manageable with no DVT or peripheral neuropathy reported. Twenty-one patients had perifosine reduced from 150 to 100 mg qd ...

Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash

... with bortezomib included thrombocytopenia (Grade 3-4 at 1.3 mg/m2) and neuropathy (Grade 1-2, at 1.3 mg/m2). A lower than anticipated rate of neuropathy was observed in the tanespimycin plus bortezomib combination, and no ...

Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer

... - Phase 1 CRC Data Support Picoplatin's Lack of neuropathy and Use in Combination Therapy - SOUTH SAN ... can be administered safely in this patient population. In the trial, no neuropathy greater than grade 1 has been observed in all patients treated, including ...

The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy

... peripheral neuropathy. Conditions associated with diabetic peripheral neuropathy include numbness, skin ulcers, constant pain or extreme sensitivity to ... issued on a Phase II(b) Clinical Study of QR-333 on Diabetic Peripheral neuropathy stating that over 100 subjects had been enrolled, 52 subjects had ...

Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer

... and nutrition: Common: Dehydration. Nervous system: Very common: neuropathy - sensory. Common: neuropathy - motor, dysgeusia. Renal and urinary: Very common: Creatinine elevation, ...

NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study

... chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with ...

Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology

... Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other ...

Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech

... Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other ...

CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders

... the effects of nerve growth factor (NGF). CeNeRx intends to initiate a Phase l trial of CXB909 for the treatment of chemotherapy-induced peripheral neuropathy (CIPN) later this year. "Nerve growth factor has long been of interest as a potential therapy for neuropathies and neurodegenerative diseases, ...

NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia

... chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with ...

Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting

... peripheral neuropathy, a common side effect associated with the approved proteasome inhibitor, bortezomib. Exacerbation of pre-existing peripheral neuropathy was rare and did not result in dose reductions or discontinuation of therapy. Overall, adverse events did not limit treatment duration, even among ...

AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria

... PBGD protein in an animal model of AIP. In this model, the therapy completely prevented the occurrence of attacks and significantly ameliorated the neuropathy that develops in untreated mice. AMT-021 is intended to provide long-term normalization of the PBGD protein in order to prevent acute porphyric ...

Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)

... radiographic evidence of demyelinating disease. Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA; the causal relationship to CIMZIA remains unclear. Exercise caution in considering the use of ...

Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update

... is associated with significant side effects including neuropathy, which can limit its use and result in its discontinuation. Effective first-line, neuropathy sparing treatment for CRC is a major unmet medical need. About Prostate Cancer More than 1 million American men are currently living ...
Other Contents
(Date:8/19/2014)... . Taking ... activity in children,Today the Canadian Society of Exercise Physiology ... activity and published their position and recommendations in the ... APNM ). This position stand provides an important ... physical activity for children and suggests both practical guidelines ...
(Date:8/19/2014)... Although body motion sensors already exist in different forms, ... complexity and cost of production. Now researchers from the ... the first time treated common elastic bands with graphene, ... for medical use and can be made cheaply. ... By fusing this material with graphene - which imparts ...
(Date:8/19/2014)... that protect their young have bigger brains than counterparts ... of British Columbia study. , Stickleback fish are well ... the male of the species, rather than the female, ... than females and researchers wanted to find out if ... as caregivers. , In the study, published recently ...
Breaking Biology News(10 mins):Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 3
(Date:8/19/2014)... 19, 2014 Kars4Kids , a ... announced today its partnership with New York State Senator ... in the Bronx. The giveaway will take place in ... Crotona Park on August 22. , “With a ... believe properly preparing children for school with the necessary ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 Top10BestSEOHosting.com has ... GoDaddy and iPage are the most recommended ... Joomla hosting (including VPS and cloud hosting) at an ... competitively priced products and service with some of the ... free). They give their loyal customers a lot of ...
(Date:8/19/2014)... 2014 Grande Naturals, LLC is ... of the 2014 Independent Cosmetics Manufacturers & Distributors ... place position in “Product Innovation; Product Color Cosmetic” ... also includes a lash enhancement serum, GrandeLINER™. ... technology. , This all-new eyeliner is ...
(Date:8/19/2014)... HealthDay Reporter TUESDAY, ... be added to the list of possible harms related ... treat behavioral symptoms of dementia in older adults, a ... olanzapine (Zyprexa) are approved by the U.S. Food and ... serious mental disorders. They are also frequently used "off-label" ...
(Date:8/19/2014)... York (PRWEB) August 19, 2014 As ... Bernstein Liebhard LLP notes the publication of a new ... may increase the risk of acute kidney injury in ... Ottawa Citizen, the study was conducted by researchers at ... the Institute for Clinical Evaluative Sciences, and looked at ...
Breaking Medicine News(10 mins):Health News:Backpack Giveaway Kars4Kids Partners with New York State Senator Gustavo Rivera to Prepare Bronx Students for New School Year 2Health News:Top10BestSEOHosting.com: Cheap Joomla Hosting Reviews Unveiled 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 3Health News:Certain Antipsychotic Meds Tied to Kidney Problems in Elderly 2Health News:Certain Antipsychotic Meds Tied to Kidney Problems in Elderly 3Health News:As Risperdal Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Linking Atypical Antipsychotic Medications to Kidney Damage in Elderly Patients 2Health News:As Risperdal Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Linking Atypical Antipsychotic Medications to Kidney Damage in Elderly Patients 3Health News:As Risperdal Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Linking Atypical Antipsychotic Medications to Kidney Damage in Elderly Patients 4
Other TagsOther Tags